3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Urinary Bladder Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Medulloblastoma
1
Lung Neoplasms
1
Leukemia, Hairy Cell
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Ependymoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma in Situ
1
Breast Neoplasms
1
Interventions
pembrolizumab
91
Carboplatin
79
Specimen Handling
76
Magnetic Resonance Spectroscopy
64
Pemetrexed
60
Cisplatin
49
durvalumab
44
Paclitaxel
38
Nivolumab
34
atezolizumab
32
Radiotherapy
30
Radiosurgery
30
osimertinib
29
Blood Specimen Collection
27
Biopsy
26
Gemcitabine
24
Docetaxel
24
Immunoglobulin G
23
Standard of Care
22
Disulfides
22
Etoposide
21
Drug Therapy
21
Taxes
18
Practice Guidelines as Topic
18
Radiation
17
Educational Status
16
130-nm albumin-bound paclitaxel
15
X-Rays
14
Surveys and Questionnaires
14
Bevacizumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Histamine Antagonists
×
1 year
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled